Dingding Shi's questions to Beigene Ltd (ONC) leadership • Q4 2024
Question
Dingding Shi of Jefferies inquired about the key assumptions underpinning the 2025 revenue guidance of $4.9 billion to $5.3 billion and the factors that could influence the final outcome. She also sought confirmation on the data disclosure timing for the B7-H4 ADC and CDK2 inhibitor programs.
Answer
CFO Aaron Rosenberg explained that the guidance is driven by continued U.S. market share gains for BRUKINSA, the lapping effect of 2024 new patient starts, stable net pricing, and global expansion in Europe and new markets like Japan. Global Head of R&D Lai Wang confirmed that initial data for both the B7-H4 ADC and CDK2 inhibitor are slated for presentation at ASCO in the first half of 2025.